Kiora Pharmaceuticals, Inc. (KPRX)

Market Cap	16.16M +26.1%
Revenue (ttm)	n/a
Net Income	-10.99M
EPS	-2.30
Shares Out	6.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,488
Open	2.515
Previous Close	2.530
Day's Range	2.515 - 2.570
52-Week Range	1.765 - 2.910
Beta	-0.21
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About KPRX

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 13
• Stock Exchange: Nasdaq
• Ticker Symbol: KPRX
• Website: https://www.kiorapharma.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error